At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
ANVS Annovis Bio, Inc.
Closed Mourning Day 01-08 16:00:00 EST
5.16
+0.11
+2.18%
盘后5.00
-0.16-3.10%
19:54 EST
High5.27Low4.65Vol539.00K
Open5.01D1 Closing5.05Amplitude12.28%
Mkt Cap71.19MTradable Cap56.67MTotal Shares13.80M
T/O2.67MT/O Rate4.91%Tradable Shares10.98M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--
Annovis Bio: Strategic Advancements and Phase 3 Trial Acceleration Justify Buy Rating
TIPRANKS  ·  01:55
Annovis Bio: Strategic Advancements and Phase 3 Trial Acceleration Justify Buy Rating
BUZZ-U.S. STOCKS ON THE MOVE-Annovis Bio, Hoth Therapeutics, Digital Realty
Reuters  ·  01-08 02:39
BUZZ-U.S. STOCKS ON THE MOVE-Annovis Bio, Hoth Therapeutics, Digital Realty
Annovis Bio Says FDA Approved Revised Protocol for Phase 3 Alzheimer's Disease Study
MT Newswires Live  ·  01-08 00:21
Annovis Bio Says FDA Approved Revised Protocol for Phase 3 Alzheimer's Disease Study
BUZZ-Annovis Bio rises as FDA approves late-stage Alzheimer's study protocol
Reuters  ·  01-07 22:16
BUZZ-Annovis Bio rises as FDA approves late-stage Alzheimer's study protocol
Annovis Bio announces FDA acceptance of protocol for Phase 3 AD study
TIPRANKS  ·  01-07 21:16
Annovis Bio announces FDA acceptance of protocol for Phase 3 AD study
BRIEF-FDA Accepts Final Protocol For Pivotal Phase 3 Alzheimer’S Disease Study, Streamlining Development Pathway
Reuters  ·  01-07 21:13
BRIEF-FDA Accepts Final Protocol For Pivotal Phase 3 Alzheimer’S Disease Study, Streamlining Development Pathway
FDA Accepts Final Protocol for Pivotal Phase 3 Alzheimer’s Disease Study, Streamlining Development Pathway
THOMSON REUTERS  ·  01-07 21:00
FDA Accepts Final Protocol for Pivotal Phase 3 Alzheimer’s Disease Study, Streamlining Development Pathway
Annovis Bio Inc - Revised Protocol Includes 6-Month Symptomatic and 12-Month Disease-Modifying Assessment
THOMSON REUTERS  ·  01-07 21:00
Annovis Bio Inc - Revised Protocol Includes 6-Month Symptomatic and 12-Month Disease-Modifying Assessment
Annovis Bio Inc - Integrates Phase 3 Ad Studies Into Single 6/18-Month Trial
THOMSON REUTERS  ·  01-07 21:00
Annovis Bio Inc - Integrates Phase 3 Ad Studies Into Single 6/18-Month Trial
FDA Accepts Final Protocol for Pivotal Phase 3 Alzheimer’s Disease Study, Streamlining Development Pathway
GlobeNewswire  ·  01-07 21:00
FDA Accepts Final Protocol for Pivotal Phase 3 Alzheimer’s Disease Study, Streamlining Development Pathway
BUZZ-U.S. STOCKS ON THE MOVE-Gold miners, Tesla, ADM
Reuters  ·  2024-12-12
BUZZ-U.S. STOCKS ON THE MOVE-Gold miners, Tesla, ADM
BUZZ-U.S. STOCKS ON THE MOVE-Exxon Mobil, Mondelez International, Macy's
Reuters  ·  2024-12-11
BUZZ-U.S. STOCKS ON THE MOVE-Exxon Mobil, Mondelez International, Macy's
BUZZ-Annovis Bio falls on planned $50 mln share sale
Reuters  ·  2024-12-11
BUZZ-Annovis Bio falls on planned $50 mln share sale
BRIEF-Annovis Bio Enters Equity Distribution Agreement With Oppenheimer
Reuters  ·  2024-12-11
BRIEF-Annovis Bio Enters Equity Distribution Agreement With Oppenheimer
Annovis Bio Inc - to Offer up to $50 Million in Common Stock
THOMSON REUTERS  ·  2024-12-11
Annovis Bio Inc - to Offer up to $50 Million in Common Stock
Annovis Bio Inc - Enters Equity Distribution Agreement With Oppenheimer
THOMSON REUTERS  ·  2024-12-11
Annovis Bio Inc - Enters Equity Distribution Agreement With Oppenheimer
Annovis Bio Inc - Appoints William Fricker as Interim CFO
THOMSON REUTERS  ·  2024-12-10
Annovis Bio Inc - Appoints William Fricker as Interim CFO
Annovis CEO Showcases Groundbreaking Advances in Neurodegenerative Disease Treatment on Today’s Marketplace
GlobeNewswire  ·  2024-12-05
Annovis CEO Showcases Groundbreaking Advances in Neurodegenerative Disease Treatment on Today’s Marketplace
Annovis to Host Year-End Investor Webcast on December 11, 2024
GlobeNewswire  ·  2024-11-25
Annovis to Host Year-End Investor Webcast on December 11, 2024
Strategic Buy Rating on Annovis Bio Amid Regulatory Alignment and Growth Potential in Alzheimer’s Market
TIPRANKS  ·  2024-11-15
Strategic Buy Rating on Annovis Bio Amid Regulatory Alignment and Growth Potential in Alzheimer’s Market

Introduction

Company Name.
Annovis Bio, Inc.
Affiliated Markets:
NYSE
Listing Date:
--
Main Business:
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead product candidate is Buntanetap, which is in Phase 3 clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, and other chronic neurodegenerative diseases. It is also developing ANVS405 for protecting the brain after traumatic brain injury and/or stroke; and ANVS301, which is in Phase I clinical trials to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Berwyn, Pennsylvania.
Issue price:
--